Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other hematologic neoplasm 1Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Ovarian Neoplasms 1Hematologic Neoplasms 1Cholangiocarcinoma 1Carcinoma, Non-Small-Cell Lung 1

Interventions

aflibercept 2Surveys and Questionnaires 2Polymerase Chain Reaction 2Methods 2Magnetic Resonance Spectroscopy 2Gene Expression Profiling 2Early Intervention, Educational 2Counseling 2Bupropion 2Blood Specimen Collection 2ulixertinib 1trastuzumab biosimilar HLX02 1trametinib 1sapanisertib 1relatlimab 1pertuzumab 1palbociclib 1osimertinib 1omipalisib 1margetuximab 1larotrectinib 1ipatasertib 1erdafitinib 1entinostat 1defactinib 1dabrafenib 1copanlisib 1capivasertib 1binimetinib 1adavosertib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × margetuximab × Other hematologic neoplasm × Clear all
NCT03219268 2023-12-21

A Study of MGD013 in Patients With Unresectable or Metastatic Neoplasms

MacroGenics

Phase 1 Completed
277 enrolled
BreastGastrointestinalGynecologicHead & NeckOther hematologic neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Ovarian Neoplasms, Cholangiocarcinoma, Hematologic Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡